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Various chincric ET,, and ET,, receptors were produced in CHO cells for the elucidation of a specific domain which influences the afinity of the 
receptor toward BQ-123, a sclrctive ET,, antagonist. Replacement of the first cxtmcellular loop domain (B-loop) of the ETA receptor with the 
corresponding domain of the ET,, receptor, reduced the inhibition by BQ-123 drastically, while the replacements of other extracellular domains 
of ET,, did not. By contrast. the introduction of the B-loopof ET, in place ofthecorrapondingdomain ofthe ET,, receptor endowed the ETs-based 
chimeric rcccptor with a sensitivity to BQ-I 23. Thcsc observations suggest that the B-loop domain of the ET,, receptor is involved in ligand binding. 
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I. INTRODUCTION 
Endothelin (ET), a 21-amino acid peptide, induces 
strong and long acting vasoconstriction in a wide vari- 
ety of vascular beds, and serves as an important modu- 
lator of vascular tonus [l]. There are three isoforms of 
endothelin: ET-I, ET-2 and ET-3 [2]. Concerning its 
receptor, there are at least two types of endothelin re- 
ceptors. ET, and ET,, [3]. The ETA receptor is predom- 
inantly located in vascular smooth muscle cells [4,5], 
where it plays a major role in vasoconstriction; the ETI, 
receptor is predominantly located in vascular cndothe- 
lium cells [5,6] and is linked to vasodilation through the 
release of endothelium-derived relaxation factor and 
prostacycline [7,8]. We have cloned cDNAs coding for 
human ET, and ETU receptors [9,10]. The cloned 
cDNA sequences indicated that both ET,, and ET, are 
members of the seven transmembrane-spanning and G- 
protein-coupled receptor family [4,9,11]. Both of the 
cloned cDNA have recently been expressed in the trans- 
fected COS cells [9,10]. The expressed ETA receptor 
represented different afinities to three endothelin 
isoforms in the order of ET-1 > ET-2 3> ET-3 [5,9], 
while the ET” binds to ET-l, 2 and 3 with an almost 
equal affinity [6. I I]. 
Cu~ss~~~rr~~~c ~ kirw: Y. Furuichi, Dcpartmcnt of Molecular Ge- 
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Several receptor antagonists have been reported, 
which compete with endothelins for binding to receptor 
and block the G-protein-mediated signal transduction 
and calcium channeling. The antagonist hat inhibits 
the ETA or ETll receptor specifically or inhibits a certain 
step in signal transduction, provides a powerful tool for 
the elucidation of the functional domains of the receptor 
structure. BQ-123 is a novel cyclic pentapeptide, cyclo(- 
D-ASP-L-PrO-D-Val-L-Leu-D-Trp-), and binds to the ET- 
1 selective ETA receptor, but not to the ligand non- 
selective ETB receptor [12]. In this paper, the structure 
and function of two ET receptor species were investi- 
gated by construction and production in CHO cells of 
various chimeric receptors, and by inhibition of their 
activities by the ET,-specific antagonist BQ-123. 
2. MATERIALS AND METHODS 
2.1. Murcrials 
ET-1 was purchased from Pcptide Institute Inc. (Osaka, Japan) nad_ 
the “jI-labeled ET-I (81.4 TBq/mmol) was from New England Nu- 
clear. The site-dircctcd mutagenesis ystem, Mutan-K, was from 
Takara Co. Ltd. (Osaka, Japan). 3-[(3cholamidopropyl)dimclh- 
ylammoniol-I-propanesulfonate (CHAPS) and Fun-2 (Fura-lpcnta- 
aceloxymethylcstcr) was from Dojin Chemical lnslitutc Co. 
(Kumamoto, Japan). BQ-123 was chemically synthesized and purified 
to homogeneity. Details of the proccdurc will be described elscwherc. 
CHO cells were cultured in Dulbccco’s Modified Eagle Medium 
(DMEM) (Gibco Laboratories, New York, USA) supplemented with 
heat-inactivated 10% fetal bovine serum. The cells were grown at ca. 
3 to 4 x 10” cells per 90 mm-diameter dish 1 day before transfection 
and the medium was replaced with 6 ml of DMEM supplcmcnted with 
heat-inactivated 10% Nu-serum. About 8 fig of pCDM%-based chim- 
eric plasmids in 100 .ul of distilled water and 60 yl of 40 mdml of 
DEAE-dextran in phosphate-buffered saline were mixed with vortcx- 
ing and added to the cell monolayer. After ths further addition of 60 
~1 of IO mM Chloroquine (Sigma Co., St. Louis. USA), the mixture 
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was incubated for 3 h. Cells were treated with 3 ml of 10% dimethylsul~ 
I’oxidc l’or 3 min, and were I’ed with fresh medium again and incubuted 
for 72 h prior to ligand binding or Cal* induction irssays, 
CHO cells were rcmovcd from the monolayer plates and collected 
by centrifugation. Aner sonicalion ol’CH0 cells, the crude mcm brane 
was prepared from the ccl1 homogenate by centril’ugation ai 50.000 
rpm for 20 min, and the pellet was suspended in200~1 of assay bulTer 
(50 rnM sodiuln phosphate buffer, pH 7.4, and 0.1% CHAPS), The 
assay mixture (50 ,UI) consists of 30 ~1 of assay buffer, I5 ~1 or crude 
membrane from transfected CHO cells, 2.5 linolcs of “Wabclcd ET- I 
and 10-~U-16-5 M BQ-123. It was incubn:ed for 2 h at room tcmpera- 
ture. The receptor-[“‘I]ET~l complex was separated from lice 
[lz’I]ET~I and determined the radioactivity of the bound ET-I as 
described [13]. Non-specific binding was determined in the presence 
or 1 ,uM nonradioactive ET-I. 
Three days slier transfeclion, the CHO cells were treated with 
trypsin, washed twice with soluGon A (140 mM NaCI. 4 mM KCI, I 
mlM Na2HPOa, I mM MgC&, I .25 mM C&II, I I mM glucose. 5mM 
HEPES butTcr, pH 7.4, 0.2% bovine serum albumin) and incubated 
in solution A conlaining IO ,uM Fura- for I h at 2OOC. The Fura-?- 
louded cells were washed twice and resuspended in 4.5 ml or rresh 
solution A whhout the dye. After lransfkr or one ml aliquoi of the cell 
suspension to the &umber of the intracellular ion analyzer (Japan 
Spectroscopic Co., Tokyo, Japan). ET-1 was added ai a final concen- 
tntion of I nM and the Iluorescencc or the cells was measured with 
cnchotion at 340 nm and 380 nm, and emission ai 500 IIIII. Next, 
BQ-123 was added to another one ml aliquot of the FuraG-loaded cell 
suspension i  the chamber at the final concernration of 1 PM, I min 
and 20 s beTore the addition of lO+‘M ET-l, and ET-I induced [GI~~]~ 
was measured. The tolal intracellular calcium concentrations or irans- 
rected CHO cells before and arter the addition of ET-I were deter- 
mined as described [ 14.15]. 
3. RESULTS 
3.1. Expressiort of citimeric ET receptors 
We have constructed pCDM8-based expression plas- 
mids to synthesize various chimeric ET receptors, in 
which each extracellular domain, A, B, C and D of ET, 
receptor, was replaced with the corresponding domain 
of the ETI, receptor. List of these chimeric receptors is 
shown in Fig. 1. After transfection of CHO cells with 
these plasmids, the binding of “51-labeled ET-I to the 
receptor was determined as described in section 2. The 
parental and chimeric ET receptors bound 0.6 to 2.2 
frnol range of “51-labeled ET-I in the assay condition 
described in section 2. 
3.2. D&ferenrid effect of Be-123 011 the ligcmd bi~dhg 
uctivity of various cltimeric ET receptors 
BQ-123 was reported to be a ET,-specific antagonist 
[12]. We have synthesized BQ-123 to investigate its in- 
hibitory effect on the ligand binding activity of chimeric 
ET receptors. The synthesized BQ-123 indeed inhibited 
the [“‘I]ET-1 binding in an ET,-specific mauler: the 
bindi.ng ICsO was 6 nM for the ETA and more than 10 
AM for the ETB receptor (Fig. 2(l)). When the N-tern& 
nal half of ETA receptor was substituted with the corre- 
sponding half of ET,, receptor (Fig. lK), the resulting 
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^ (A) ETA (E) ETA-D (I) ETB-C 
(B) ETA= A (F) ETB (J) ETB-D 
(C) ETA-B (G) ETB-A (K) ETA-AB 
(D) ETA-C (H) ETB-B (L) ETA-CD 
Fig. I. Structure ol’chimeric ET reccpiors. (A) ET,, recepior. (F) ETB 
rLrcptor. (K snd L) HalToTET,., receptor was replaced by that of ET,, 
receptor and vice versa. Numbers on the chimeric receptors represent 
the regions of changed amino acid sequences or the parental ET 
rcccptor: ET,,-CD (212-427 or C-terminus), ET,,-AB (l-210), (B-D 
and G-I) Each of the cxlracelluhr .4, B and C domains of ETA 
receptor was replaced by the same domain oT ETl, roceplor and vice 
verba. To construci the expression plasmids for various chimeric ET 
another ET reccpior through several ligation steps. The following 
amino acid sequences ofET,, receptor were substituted whh the corrc- 
sponding sequences of’ the ET,, receptor and vice versa. Numbers on 
the chimcric receptors represent the regions or changed amino acid 
sequences ol’ the parental ET receptor: ET,,-A (l-79), ETA-B (l39- 
l75), ET,-C (229-270), ET,,-A (l-120), ETB-B (l38-l97), ET,& 
(241-291). (E and J) D domains of the ET,, and ETl, receptors were 
mutuully exchanged. ET,, ilnd ET,,cDNAs were subcloned in the XbuI 
site or Ml 3-mpl9 plasmid vector imd wcrc subjected to site-directed 
mtnagenesis u ing the Kunkel procedure [ 161, The nucleoiide sequence 
encoding the D-loop domain of ET,, receptor was clmgcd to that of 
the ET, receptor. The same approach was done to form the chimcric 
ET,, receplor that conlains the D-loop ol’ the ET,. The mutated 
cDNAs were inserted into Xbd she of pCDM8 vector at correct 
orientation. The resultunt plasmids were designated as ET,-D and 
ET,,-D, The closed bar und open bar represent the sequences ofhuman 
ET,, and ET” rcwptor, respectively. The extracellular A, B, C and D 
domains are indicated. 
chimeric receptor, surprisingly, showed a strong resis- 
tance to inhibition by BQ-123. The coccentralion of 
UQ-123 required for 50% inhibition (I&) went up from 
G nM (to ETA receptor) to over 10 ,uM for this chimeric 
receptor (Fig. 2( 1)). By contrast, the substitution of the 
C-terminal half of ET, with that of ET,, receptor (Fig. 
I L) showed only a subtle change in the I& of BQ- 123 
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Fig. 2. Inhibitory elikts of BQ-123 on the ligand binding of parental 
and chimeric ET receptors transiently expressed in CHO cells. (I) 
human ET,, (II) and ET, (0) rwsptors. ET,,-CD (m) and ETA-A6 (e) 
chimeric receptors; (2) human ETA receptor (0) and the chimcric 
ETA-A (E), ETA-B (o), ET,,-C (a)and ET,,-D (+) rcccptors; (3) human 
ETU (0). ET,,-A (o), ET,,-B (m), ET& (A) and ET& (+) receptors. 
(Fig. 2(i)). These results suggest hat the N-terminal 
half which includes A and B-domains of ETA is respon- 
sible for the specific inhibition by BQ-123. 
Next, WC have constructed a series of recombinant 
chimeric receptors to investigate in detail the regions 
that influence the inhibition profile of BQ-123. Each 
individual domain of ET,, the A, B, C and D domains, 
was replaced with the corresponding region of ETs re- 
ceptor. Furthermore, the construction of various chim- 
eric receptors with the same replacements were carried 
out for ET, receptor. The substitution of each of A, C 
and D domain of the ET,,, receptor with each of the 
corresponding region of the ETB receptor (Fig. 1 B,D,E) 
caused only a marginal decrease in the inhibitory activ- 
ity of BQ-123, to less than one-tenth-fold of the original 
inhibitory activity (Fig. 2(2)). However, when the B- 
loop domain of the human ETA receptor was substi- 
tuted with the same domain of the ETs receptor (Fig. 
IC), a drastic decrease in antagonistic activity (more 
than l/100-fold) of BQ-123 was observed (Fig. 2(2)). 
Conversely, when the B-loop domain of ETB rcwptor 
was substituted with that of the ET, receptor (Fig. 1 H), 
the relative antagonistic activity of BQ-123 was in- 
creased by more than one order of magnitude (Fig. 
2(3)). Thus, the B-loop domain of ETA receptor must be 
involved in the interaction with BQ-123. 
3.3. Effect of Be-123 on rite ET fnducecl increase of the 
The [Ca?‘], increased from the 27-77 nM range to the 
73-290 nM range, by the addition of IO-” M ET-1 to 
CHO cells which were transfected with expression plas- 
mids pCDM8-ET,,:aJa nd chimeric plasmids. As ex- 
pected, SQ-123 inhIbIted the ET-induced transient in- 
crease of [Ca’+]i in CHO cells transfected with pCDMS- 
ETA, but it did not inhibit the increase in CHO cells 
transfected with pCDMS-ET,, (Table 1). Therefore, BQ- 
123 inhibited ET-l binding without any effect on the 
downstream pathway of signal transduction by which 
the transient increase of [Ca”], is induced. 
The effect of BQ-123 on transient increase of [Ca’+]i 
in the transfected CHO cells was examined in detail. 
When the B-loop region of the human ET,, receptor was 
substituted with the corresponding region of the ETa 
receptor, the inhibition percentage of the ET-l-induced 
transient increase of [Ca”], by BQ-123 decreased from 
98% to 70% (Table I). When the crude membranes were 
prepared from both recombinant CHO cells, BQ-123 
inhibited the binding of ‘251-labeled ET-1 to the ET, 
and ETA-B receptors by 99% and 51% at the concentra- 
tion of 1 PM, respectively (Fig. 2). On the contrary, 
when the B-loop region of ETs receptor was substituted 
with the corresponding region of ET,, receptor, the inhi- 
bition percentage by BQ-123 increased from 24% to 
89% under the same experimental conditions (Table I). 
The exchange of A, C and D domains between ETA and 
ETa receptors, however, did not significantly affect the 
extent of inhibition by BQ-123 for the transient increase 
of [Ca’+]i (Table I). Again, these results indicate that the 
B-IOOD domain of the ET,A receptor is a site which inter- 
acts with BQ-123. The same domain of ETs receptor, 
for yet unknown reasons, does not interact with BQ- 
123. 
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Table 1 
Inhibition by BQ-123 of ET-I induced trnnsicnt increusc of [Caz*]i in transfected CHO cells 
ET receptors 
Basal 
Intracellular Caz’ conccntmtion 
IO-” M ET-I Basil IO-6 M BQl23 
und lo-” M ET-1 
Inhibition (%) 
by BQl23 
ETA 
ET,,-A 
ETA-B 
ETA-C 
ET,-D 
B-fa 
ET,,-A 
ET,,-B 
ETa-C 
ET,,-D 
ETA-CD 
ET,-AB 
76 nM 
45 nM 
34 nM 
63 nhl 
44 nM 
56 nM 
69 nM 
64nM 
55 nM 
71 nM 
21 nM 
29 nM 
220 nM 
I20 nM 
95 nM 
I60 nM 
290 nM 
140 nM 
250 nM 
240 nM 
220 nM 
250 nM 
86 nM 
13 nM 
26 nM 
47 nM 
39 nM 
63 nM 
45 nM 
3G nM 
I? nM 
G7 nM 
41 nM 
54 nM 
39 nM 
39 nM 
29 nM 
41 nM 
51 nM 
63 nM 
45 nM 
100 nM 
250 nM 
8-l nM 
200 nM 
250 nM 
42 nM 
91 nM 
98% 
100% 
70% 
100% 
100% 
24% 
2% 
89% 
4% 
4% 
95% 
0% 
Increase of intracellular calcium concentration by the addition of lO‘y M ET-l, and the inhibition by I PM BQ-123 was dctcrmined as described 
in section 2. Inhibitory elrect of BQ-123 on the ET-induced increase ol’ [CL?+], was determined and represented by percentages. 
4. DISCUSSIQN 
It has been reported that the C-terminal domain of 
ETs, especially the tryptophan residue at the C-termi- 
nus, plays an important role in the binding of ETs to 
the receptor [17,18]. Supporting this hypothesis, the 
peptidic endothelin antagonists, BQ- I23 and FR- 
1393 17 (I-hexahydroazepino-CO-Leu-o-Trp(CH&n- 
(2-pyridyl)alanine), and the agonist, IRL-1620, Suc- 
[Glu”,Ala~‘~‘5]-ET-l(8-21) [19], that contain C-terminal 
tryptophan residue, have been found to be specific ET 
antagonists or agonists. The two former antagonists are 
ET,-specific and the latter agonist is ET,-specific. All 
these peptidic compounds apparently bind to the endo- 
thelin receptor through the structural resemblance of 
the -Asp(Leu)-ProlAsp)-Val(Ile)-Leu(Ile)-Trp-sequet~ce 
to the C-terminal sequence (-Leu-Asp-Be-Be-Trp) ofen- 
dothelins. Although the processing of preprobigET and 
the second messenger pathways of ET have been exten- 
sively investigated, little is known about the function of 
each ET receptor domain. First of all, it is not clear why 
the two distinct receptor species that bind ET- 1 with an 
almost identical affinity exist in the different cells and 
tissues. The two types of receptor differ in binding to 
ET-3, while the overall structure of receptor molecule 
and the biological activity, as mea~uzed in vitro by li- 
gand binding and induction of [Ca”], increase, are quite 
similar. The significant similarity of the two ET recep- 
tors makes it difficult to define the regions required for 
ligand selection and binding. iXJ-i23, kt ~lrljng ET, 
specific inhibitor, is thus one of few valuable reagents 
that can distinguish the binding site of the ETA receptor 
from ETa receptor. 
To assess the structural alterations of chimeric recep- 
tors that result in the changes in the prol’lle of ligand 
binding, we used BQ-123 as a diagnostic reagent. The 
substitution of the B-loop of the ETA receptor wit11 the 
same region of ETa receptor emarkably reduced the 
affinity by BQ-123, indicating that BQ-123 perhaps 
binds to the B-loop of the ETA receptor, but not, or 
weakly, to the B-loop of ET, receptor. As shown in the 
experiments (Table I) in which the ET-dependent [Ca’+li 
was monitored in CHO cells that express chimeric re- 
ceptors, BQ-123 inhibited the ET-l-induced increase of 
[Ca’+]i significantly when the B-loop of ETA was present 
in the chimeric receptor, in accordance with the in- 
creased inhibition in ligand binding, The results indi- 
cated that BQ-123 is not an agonist and is a useful 
reagent hat competes with ET-1 at the ligand binding 
step only. 
Recently, we have found that part of the N-terminal 
extracellular domain (amino acid residues 50-76 of the 
predicted human ET, sequence), in the vicinity of the 
first transmembrane, is required for ET-l binding [20]. 
The data indicates tha,t part of the N-terminal domain 
is involved in the tertiary structure formation of ligand 
binding site, together with the B-loop domain of the 
ET.,, receptor. 
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